CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 805 enrolled / 805 target
Drug / intervention
olaparib +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04269200
NCT04269200Phase 3ActiveUpdate Overdue (10.9/mo)Completion was 23mo ago
CompareCT.gov

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

AstraZeneca·interventional·Posted Feb 13, 2020·Updated Jun 1, 2026

In Brief

A Phase 3 clinical trial evaluating olaparib, durvalumab, and 4 other interventions for Endometrial Neoplasms. Active but no longer recruiting, targeting 805 participants across 201 sites in 22 countries.

Signals

Enrollment appears stalled

Detailed Summary

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Neoplasms
CountriesAustralia, Belgium, Brazil, Canada, China, Colombia, Estonia, Germany, Greece, Hong Kong, Hungary, India, Israel, Japan, Lithuania, Mexico, Poland, Russia, Singapore, South Korea, Spain, United States
CollaboratorsGOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)

Timeline

Phase 3Active
20202021202220232024202520262027
First PostedFeb 13, 2020
Enrollment StartMay 5, 2020
Primary CompletionJul 8, 2024
Study CompletionApr 1, 2027
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 6.4 years ago

Arms & Interventions

Arm A (control)active_comparator

Platinum-based chemotherapy and durvalumab placebo followed by maintenance durvalumab placebo and olaparib placebo (tablets).

Drug: durvalumab placeboDrug: olaparib placeboDrug: CarboplatinDrug: Paclitaxel
Arm B (durvalumab+placebo)experimental

Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib placebo

Biological: durvalumabDrug: olaparib placeboDrug: CarboplatinDrug: Paclitaxel
Arm C (durvalumab+olaparib)experimental

Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib.

Drug: olaparibBiological: durvalumabDrug: CarboplatinDrug: Paclitaxel

Interventions

olaparibdrug

Olaparib tablets

durvalumabbiological

Durvalumab by intravenous infusion

durvalumab placebodrug

Matching placebo for intravenous infusion

olaparib placebodrug

Placebo tablets to match olaparib

Carboplatindrug

Standard of care chemotherapy

Paclitaxeldrug

Standard of care chemotherapy